HS
RNAC icon

HighVista Strategies’s Cartesian Therapeutics RNAC Stock Holding History

HighVista Strategies’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-742
Closed -$92K – 107
2021
Q3 		$92K Buy
+742
New +$89.6K 0.06% 109

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighVista Strategies's RNAC Position: Q4 2021 in Review

HighVista Strategies sold out of Cartesian Therapeutics (RNAC) in Q4 2021, closing a stake of 742 shares — an estimated $92K sold.

HighVista Strategies first reported a position in RNAC in Q3 2021 and held it in 1 quarter. The position peaked at $92K in Q3 2021. 106 funds tracked by Wall St. Rank hold RNAC as of Q4 2021.

  • HighVista Strategies reported no remaining Cartesian Therapeutics position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 742 Cartesian Therapeutics shares in Q4 2021, an estimated $92K.
  • HighVista Strategies first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 1 quarter.
  • HighVista Strategies's Cartesian Therapeutics position peaked at $92K in Q3 2021.
  • 106 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.